The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Estimated Growth In Market Size Of The Biosimilar Hormones Market During 2026–2030?
The biosimilar hormones market has undergone rapid expansion in recent years. Its size is expected to increase from $6.22 billion in 2025 to $7.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.5%. The historical growth of this market stems from factors such as the increasing prevalence of diabetes and hormonal disorders, the significant cost of branded hormone therapies, a growing aging population, rising awareness of hormone replacement therapies, and the expanding networks of hospitals and retail pharmacies.
The biosimilar hormones market size is projected to experience substantial expansion in the coming years. It is anticipated to grow to $18.12 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 23.9%. This projected growth throughout the forecast period is driven by factors such as the patent expiry of significant biologic hormones, increasing regulatory encouragement for biosimilars, a rising need for affordable endocrine treatments, the broadening of online pharmacy distribution channels, and an uptick in investment for biosimilar research and development. Prominent trends for the forecast period involve the increasing adoption of biosimilar hormones as economical alternatives, a rising demand for insulin and growth hormone biosimilars, greater acceptance of biosimilar hormone therapies among medical professionals, the expansion of biosimilar application in chronic and lifestyle diseases, and enhanced regulatory pathways that support biosimilar approvals.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp
What Key Growth Drivers Are Influencing The Biosimilar Hormones Market?
An anticipated expansion in healthcare spending is projected to fuel the advancement of the Biosimilar Hormones Market. This expenditure encompasses all financial outlays by individuals, entities, or governments directed towards health condition prevention, treatment, and management. The escalation in healthcare costs stems from progress in medical technology, where novel diagnostic instruments, treatments, and groundbreaking therapies frequently entail higher expenses, consequently elevating overall healthcare spending. This increase in healthcare expenditure encourages the adoption of biosimilar hormones by generating a need for economical treatments and broadening patient availability throughout healthcare systems. For example, data from the Centers for Medicare & Medicaid Services, a US-based agency, in December 2024 revealed that U.S. health care expenditures rose by 7.5% in 2023, reaching $4.9 trillion, equivalent to approximately $14,570 per person. Consequently, the increasing healthcare expenditure is a key factor propelling the expansion of the Biosimilar Hormones Market.
What Are The Major Segment Categories Within The Biosimilar Hormones Market?
The biosimilar hormones market covered in this report is segmented –
1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types
2) By Application: Research & Biotechnology, Therapeutics, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics
Subsegments:
1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance
2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)
3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management
4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders
5) By Other Types: Thyroid Hormones, Corticosteroids
What Trends Are Affecting The Growth Of The Biosimilar Hormones Market?
Leading companies in the biosimilar hormones market are developing innovative products, such as Sogroya (somapacitan-beco) injection, to boost their market profitability. Sogroya (somapacitan-beco) is a prescribed analog of human growth hormone (GH) used to treat individuals diagnosed with growth hormone deficiency (GHD). For instance, in April 2023, Novo Nordisk, a Denmark-based pharmaceutical company, received FDA approval for a new indication for Sogroya (somapacitan-beco) injection to treat children aged 2.5 years and older who experience growth failure due to insufficient endogenous growth hormone secretion. Sogroya is notable as the sole once-weekly growth hormone (GH) therapy designed for both children and adults. The approval was supported by findings from the phase 3 REAL4 trial, which demonstrated Sogroya’s effectiveness in addressing growth hormone deficiency (GHD) in pediatric patients.
Which Companies Are Influencing The Biosimilar Hormones Market?
Major companies operating in the biosimilar hormones market are Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy’s Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt
Access The Complete Biosimilar Hormones Market Report:
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
Which Region Is The Primary Market For The Biosimilar Hormones Market?
North America was the largest region in the biosimilar hormones market in 2025. The regions covered in the biosimilar hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Biosimilar Hormones Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp
Browse Through More Reports Similar to the Global Biosimilar Hormones Market 2026, By The Business Research Company
Hormonal Contraceptives Market Report 2026
https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report
Biosimilar Growth Hormone Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report
Parathyroid Hormones Market Report 2026
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model